Revista médica de Chile
-
Revista médica de Chile · Mar 2019
[Proportion of patients with heart failure in a specialized clinic eligible for novel therapies].
Pharmacological treatment improves survival in patients with heart failure with reduced ejection fraction. The use of sacubutril/valsartan and ivabradine has been recently approved and incorporated in the latest guidelines. ⋯ A low percentage of our patients were eligible for these therapies. Among the causes that explain these results were clinical stability, a high percentage of patients in functional class I and being in a disease modifying treatment.